Germline BRCA1 and BRCA2 variants in a population based cohort of ovarian, peritoneal or fallopian tube cancer patients in Malaysia

@inproceedings{Lim2017GermlineBA,
  title={Germline BRCA1 and BRCA2 variants in a population based cohort of ovarian, peritoneal or fallopian tube cancer patients in Malaysia},
  author={Joanna Marie V. Lim and Sabrina Lau and Nor Syuhada Ahmad Bashah and Kah Nyin Lai and Wei Xiong Wen and Daniel J. Park and Bernard J. Pope and Tu Nguyen-Dumont and Melissa C. Southey and Lau Kee Wah and Suresh Kumarasamy and Celina Mei Yong and Karen Yong Shi. Loo and G. A. F. Ismail and Bawadi Abdullah and Gaik S Ch'ng and K. Rethanavelu and Muzhirah Aisha Md Haniffa and Winnie Peitee Ong and Lip Hen Moey and Ibraheem M . Aliyas and Mohd Rushdan Md Noor and Ahmad Mudzakkir Ahmad Mustafa and Nor Huda Mat Ali and M. F. Mohamed Jamli and Julia Omar and Kellie Jane Lim and M. J. Makanjang and N.L.C. Cheah and Shridevi Subramaniam and J.S.H. Low and Mastura Md Yusof and Cameron K Fong and Tow Shung Tan and Matin Mellor Abdullah and Yoke Ching Foo and Steven Kho and Wee Wee Sim and Beng Hock Teh and E.S.E. Ong and Zainol Abidin Ahmad and Noor Azmi Mat Adenan and Chong Kin Liam and M.C.K. Lim and Boon Kiong Lim and Meow Keong Thong and N A Mat Adenan and Soo Hwang Teo and Sook Yee Yoon},
  year={2017}
}
Background : Germline BRCA1 or BRCA2 pathogenic variants in ovarian cancer patients may be predictive of sensitivity to platinum derivatives and PARP enzyme inhibitors. Population studies have indicated a >10% prevalence of BRCA1/2 pathogenic variants with wide variance amongst ethnically different populations. We aim to establish the first population-based cohort to assess the prevalence of BRCA1/2 in ovarian cancer patients throughout Malaysia. Methods : From August 2016, women with non… CONTINUE READING